Results 11 to 20 of about 5,263,232 (399)
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
The Journal of the National Comprehensive Cancer Network, 2022 The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary ...
T. Flaig +37 more
semanticscholar +1 more source
Hub gene associated with prognosis in bladder cancer is a novel therapeutic target [PDF]
PeerJ, 2023 Objective Bladder cancer is a clinical and social conundrum due to its high incidence and recurrence rate. It is urgent to find new targets for the diagnosis and treatment of bladder cancer and improve the prognosis and survival rate of bladder cancer ...
Dengpan Fang +4 more
doaj +2 more sources
Bladder Cancer: Current Challenges and Future Directions
Medicina, 2021 Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era ...
J. Dobruch, M. Oszczudlowski
semanticscholar +1 more source
European Urology Open Science, 2023 Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response.
Evangelia Vlachou +6 more
doaj +1 more source
Urology, 1996 SummaryBladder cancer is the fourth most common cancer in England and Wales. The most common presenting symptom is macroscopic haematuria. The management options for superficial and invasive bladder cancer depend on the stage at presentation. Most superficial bladder cancers are managed by transurethral resection and cytoscopic follow-up. The prognosis
H Y, Leung, T R, Griffiths, D E, Neal
openaire +4 more sources
Annals of Urologic Oncology, 2021 Introduction To evaluate the response of patients with high-risk bacillus Calmette-Guerin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) who we treated with intravesical CG0070, a conditionally replicating granulocyte macrophage colony ...
Evan Austin +3 more
doaj +1 more source
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection
Scientific Reports, 2023 Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of BC but this remains largely ...
L. Baxter +14 more
doaj +1 more source
Cancer Research, 2022 The RNA N6-methyladenosine (m6A) writer methyltransferase-like 3 (METTL3) is upregulated in many types of cancer and promotes cancer progression by increasing expression of several oncogenes. Therefore, a better understanding of the mechanisms regulating
Z. Ni +11 more
semanticscholar +1 more source
Oncology and Therapy, 2023 In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional.
Alex Filicevas, Thomas Powles
doaj +1 more source
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca, 2020 Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has primarily consisted of platinum‐based chemotherapy.
V. Patel, W. Oh, M. Galsky
semanticscholar +1 more source